Cost–Utility of First-Line Actinic Keratosis Treatments in Finland
Author:
Funder
Leo Pharma
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s12325-015-0211-7
Reference115 articles.
1. Weinstock MA, Lee KC, Chren MM, Marcolivio K, VATTC Trial Group. Quality of life in the actinic neoplasia syndrome: the VA topical tretinoin chemoprevention (VATTC) trial. J Am Acad Dermatol. 2009;61:207–15.
2. Stockfleth E, Terhorst D, Braathen L, et al. Guideline on actinic keratoses. Berlin: European Dermatology Forum; 2010.
3. Wilson EC. Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model. Pharmacoeconomics. 2010;28:1055–64.
4. Pflugfelder A, Welter AK, Leiter U, et al. Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. J Eur Acad Dermatol Venereol. 2012;26:48–53.
5. Bernard P, Dupuy A, Sasco A, et al. Basal cell carcinomas and actinic keratoses seen in dermatological practice in France: a cross-sectional survey. Dermatology. 2008;216:194–9.
Cited by 29 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Health utilities for non‐melanoma skin cancers and pre‐cancerous lesions: A systematic review;Skin Health and Disease;2021-06-04
2. Comparison of efficacy, adverse effects and costs between 20 % ALA-PDT and 10 % ALA-PDT for the treatment of actinic keratosis in Chinese patients;Photodiagnosis and Photodynamic Therapy;2020-09
3. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland;Advances in Therapy;2020-06-09
4. Cash is king: the balance of costs and effectiveness of treatments for actinic keratosis;British Journal of Dermatology;2020-04-05
5. Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis;Advances in Therapy;2019-12-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3